The MedTech Workshop for Small and Medium Sized Enterprises (SME’s) 2017, organised by the Asia Pacific Medical Technology Association (APACMed), was held on 7 September at Amara Sanctuary Resort Sentosa, Singapore. It featured an information-packed program tailored to the needs of medical device and IVD start-ups, digital health ventures, mid-sized MedTech R&D and manufacturing businesses, as well as research institutes, investors and service providers.
Participants of the MedTech SME Workshop 2017 were provided practical, hands-on guidance and deep insights into the challenges and opportunities in the medical technology industry. Program topics included:
- The State of Medical Device Industry – Insights on Current and Future Trends
- Developing a Strategic Marketing Plan for your Medical Device
- Manufacturing Challenges Facing Start-up Device Companies
- China Regulatory Developments and Impact of UDI
- ASEAN Medical Device Directive Implementations and Singapore Update
- MedTech Product Design & Development – Enhancing Efficacy and Outcomes with Empathy and Technology
- IP Protection for Medical Devices in Asia Pacific
- Clinical Trial Management for Medical Device Start-ups
- Investment into MedTech & Digital Health in Asia
- Building Successful MedTech Distribution Channels
General Manager, Minimally Invasive Therapies Group (MITG) Medtronic
Alvin Hew is the General Manager for the MITG Group for Medtronic South East Asia. In this role, Alvin has the P and L responsibilities for the MITG (legacy Covidien) businesses for Medtronic SEA. Prior to taking on this role, he was Vice President, Regional Marketing for Surgical Innovations for Medtronic in the Asia Pacific Region. He was responsible for the marketing, strategic direction and integration of new products and technologies within the Surgical Innovation APAC region.
Alvin also oversaw market development and commercialization of Medtronic’s new integrations in the Surgical and Early Technologies space, including technologies like Super Dimension, Given Technologies and the Value Segment.
He has 22 years of experience in the Asia Pacific medical device industry through roles in sales, regional marketing and general management. Before joining Covidien, Alvin worked at Cordis, a Johnson and Johnson company, for 16 years based in Singapore and Seoul.
Alvin is a global business leader with extensive field experience within APAC and was educated and grew up in Toronto, Canada. Alvin holds a Bachelor of Science, from Queen’s University, Canada. He also holds an MBA from the University of Chicago Booth School of Business.
Head of Strategic Initiative, Emerging Asia Baxter Healthcare
CJ is the Head of Strategic Initiatives, Emerging Asia for Baxter Healthcare. He is a member of the cross-functional Emerging Asia Leadership Team. He is responsible for driving various regional strategic initiatives including strategy planning, inorganic growth opportunity evaluation, portfolio management, go-to-market model optimization, and market prioritization.
CJ built his career as a management consultant with a focus on the Life Sciences & Healthcare industry. He has rich experience in commercial strategy, business development and operational strategy, and has advised a number of leading multinational Medtech and Pharma companies in his consulting career.
CJ holds an MBA from London Business School, and a Bachelor of Engineering from National University of Singapore.
VP & CTO Kecojo Advisor to Univac Precision Engineering
Colin A. Chong is Vice President and Chief Technology Officer at KECOJO Pte. Ltd., a product development consulting company currently engaged in a joint collaboration with Univac Precision Engineering.
Colin provides technical, strategic, product development and manufacturing expertise to Singapore-based start-up companies. He helps them leverage technologies into transformative and viable devices in the medical and life science industries.
Prior to joining KECOJO, Colin held various positions in his 17-year tenure at Medtronic Diabetes in the USA. He led research, development and manufacturing efforts for implantable and external insulin pumps, continuous glucose monitoring (CGM) hardware, and single-use, sterile disposable products. As Director of Global Technology Development, he strategically led internal, external and international cross functional teams to understand market segmentation, cost & feature sensitivity, and regulatory strategies. This included product teams in Europe, manufacturing operations in Asia, and quality, regulatory, marketing, finance and clinical evaluation teams in the USA.
Colin received his Bachelor’s and Master’s degrees in Mechanical Engineering from The Ohio State University in Columbus, Ohio.
Colin holds 35 US patents with 12 more pending, and is a recipient of the President’s Award for Outstanding Innovation from Medtronic Diabetes.
Chief Operating Officer EndoMaster
Colin is the COO of EndoMaster Pte Ltd, a medical robotics company in Singapore that he formed with the co-founders. He leads the management, commercialization and product development activities at the company. His experience extends from project management at Quattro Vascular (Singapore) in setting up their operations and development of a novel peripheral balloon catheter technology, as well as project management and system engineering at CIRTEC Medical Systems, a contract design company in the US that develops new technologies for numerous medical device companies and startups.
Colin has also worked as an R&D Engineer at ALZA Corporation, Johnson & Johnson to develop a new platform for ocular drug delivery. Colin has a M.S in Bioengineering from Stanford University and a B.S. in Biomedical Engineering from Northwestern University.
Dr Arun Venkatasubramanian
Associate Director, Global MedTech Cambridge Consultants
Arun Venkatasubramanian is Associate Director of the Global Medical Technology division at Cambridge Consultants, and technology leader for their smart implantable medical devices group that helps clients develop novel, active, passive and semi-passive implantable medical devices addressing a multitude of disease states in patients. During his 7 years at Cambridge Consultants, Arun has designed and developed several novel antennas for medical and commercial applications. Most recently, Arun was one of the technical authorities on the engineering of the world’s first Bluetooth-enabled neurostimulation implant (>5cm under the skin) that permits a doctor or patient’s smartphone to communicate directly with the implant.
Prior to joining Cambridge Consultants, Arun – who earned a PhD in Electrical Engineering from the University of Alaska Fairbanks – worked as a Senior RF Engineer at Time Domain Corporation in Huntsville, Alabama, where he developed several novel ultra-wide band antennas and radio systems for the real-time tracking of assets and people inside buildings. During his 8 year stint in academia, he co-authored a discovery paper on Whistler mode waves in the Magnetosphere, and published more than a dozen peer-reviewed conference and journal papers. Arun has also been named as an inventor on 3 worldwide patents.
Partner (Foreign Lawyer) RHTLaw Taylor Wessing
Erwan Barre is a Partner (Foreign Lawyer) at RHTLaw Taylor Wessing and the firm’s Deputy Head of Corporate Practice. He joined RHTLaw Taylor Wessing in 2015 after practicing for sixteen years with Sullivan & Cromwell and Paul Hastings, two leading US law firms, in Paris and New York. Focused on corporate transactions, Erwan has extensive experience representing clients across many industries, with an emphasis in the Technology and Life Science industries.
He also has management experience, being a co-founder of Vaximax, a biotech company.
Erwan has been involved in many M&A, joint venture, capital markets and financing projects in Asia, Europe and the US, including several game changing transactions. Most of these deals were cross-border. His transactional expertise is based on leading over 60 deals, representing in the aggregate more than US$20 billion. 15 of his deals exceeded US$ 500 million in value with several in excess of US$ 1 billion. 60% of his transactions involved TMT (telecommunications, media and technology) and life science companies. He has also represented clients in other industries, including aerospace, real estate, hospitality and energy.
His clients include blue chip names as well as promising start-ups and many leading investment banks.
He has been regularly recognised as a leading practitioner in his field by professional publications, such as Chambers and Legal 500.
Erwan holds an MBA from the Neoma (ESC Reims) Business School in France (1990), a predoctoral degree (DEA) in business law from the Pantheon-Sorbonne (Paris I) University (1993), and an LL.M. degree from Columbia University in the US (1996). Erwan has worked in Singapore, Paris, New-York and London.
Erwan is admitted in France (1996) and New York (1998) and registered to practice as a foreign lawyer in Singapore.
Principal Namazie & Co.
In between private practice, she worked for several years as in-house counsel for Apple Computers Inc.
She is a law graduate from Lady Margaret Hall, Oxford University, and has a Masters degree in Corporate and Commercial law from King’s College, University of London. Farah was called to the UK Bar, and subsequently became an Advocate & Solicitor in Singapore.
Namazie & Co. was established in 2001, as an Intellectual Property and Technology law firm, and has since frequently been listed as one of Singapore’s top ten Intellectual Property law practices by international journals. Farah leads an experienced and skilled team, and together they advise and represent many prestigious international and local clients on IPR legal protection.
Ong Jeong Shing
Investment director Venturecraft Group
Mr. Ong is a key member of the Group’s investment team and oversees the Group’s investment in the MedTech and BioTech space as its investment director. He is also an entrepreneur and is actively involved in venture building.
He has over a decade of management experience in the biomedical sciences industry, ranging from technology transfers in the pharmaceutical industry to development and commercialisation of medical technologies to venture financing of startups. Mr. Ong formerly served as Principal Manager at Exploit Technologies Pte Ltd (ETPL), the technology commercialization arm of the Agency for Science, Technology and Research (A*STAR).
Mr. Ong is an engineer by training and holds a Bachelor of Engineering in Chemical Engineering and Bioengineering from the National University of Singapore. He also holds a Master of Business Administration from the University of Cambridge.
Senior Director, New Business Development Asia Pacific Johnson & Johnson Medical
Philip Kowalczyk is in charge of New Business Development and Strategy for Johnson & Johnson Medical Asia Pacific. As a member of the Regional Leadership Team, Phil focuses on developing and executing the medical device licensing & acquisition strategy in the region.
Phil started his career at Johnson & Johnson in 2008 and has transitioned through positions of increasing responsibility, including involvement in a number of significant transactions within Medical Devices.
Phil holds a Bachelor of Arts from Princeton University and a Master of Business Administration from the University of Michigan. He, his wife Meredith, and his son Graham, are based in Singapore.
Managing Director Ontogenix
Shikharesh Das is currently the Managing Director of Ontogenix Pte Ltd, Singapore. He brings many years of global experience in medical device industry with strong emerging markets track record. Previously, he held various General Management & Marketing Leadership roles at GE Healthcare and Philips Medical. As the global Director of Strategic Marketing at GE, he was exposed to various localisation and market entry challenges for med tech devices, which inspired him to set up his own company later, providing solutions in this domain. Prior to GE, he held the position of General Manager with Philips Medical ASEAN where he rationalised and implemented the distribution strategy. He holds an MBA degree from National University of Singapore.
Ontogenix focuses on market entry strategy for SME’s into new markets by working on an executable and practical implementation plan. Currently, Ontogenix’ network extends all the way from AsiaPac, into Europe and North America. The company has already stacked up an impressive number of SME and MNC clientele in within a short time, due to its innovative and focused approach.
Industry Principal- Transformational Health Frost & Sullivan
Sowmya Rajagopalan is an Industry Principal with the Healthcare Practice at Frost & Sullivan and is based in Singapore.
Sowmya has over twelve years of experience in monitoring and analyzing emerging trends, technologies and market behavior in the medical technology sector with a particular specialization in cardiovascular, orthopedics, wound management, infection prevention, minimally invasive surgery, dental and oncology sector , globally.
Her expertise includes analyzing the emerging sectors like third party services, patient centric product solutions, patient engagement solutions.
She is also involved in designing and conducting research projects based on qualitative and quantitative studies such as opportunity assessment, market feasibility and competitive benchmarking, voice of customer studies including understanding current and future trends for services, brand adoption, technology adoption, decision makers, budget trends etc. globally.
She has been part of many global trade shows and conferences, and has contributed to leading magazines globally, including Forbes.
Vice President, MedTech Asia Pacific QuintilesIMS
Mr. Singh is responsible for the growth of our medical devices & diagnostics business in Asia. He leads a team that includes Clinical Development Services, Commercial Strategy, Market Research, Regulatory Services, and Market Analytics. These services are covered by teams in key markets such as Japan, China, India, South Korea, Taiwan, Australia-New Zealand and Southeast Asia.
He has been instrumental in putting together strategic partnerships with multinational and local device companies to accelerate their clinical trials, expedite regulatory submissions, and plan and execute their strategies for business expansion in Asia.
Prior to joining QuintilesIMS, he spent seven years in management consulting, including managing an Asia Pacific healthcare practice. He implemented several strategic consulting projects for multinational biopharmaceutical and medical device & diagnostics companies, government agencies, and financial institutions in Asia.
He also served as the Chairman for BioSingapore, an industry association that has played an integral role in developing Singapore’s biomedical sector.
Mr. Singh holds a bachelor’s degree in biomedical sciences from the National University of Singapore; a graduate diploma in bio-entrepreneurship from the University of Pennsylvania; and an MBA from the Graduate School of Business, University of Chicago.
Director Regulatory Affairs Global Strategic Regulatory Abbott
Victoria has over 10 years of policy and regulatory experience in both multi-national pharmaceutical , medical device and US-based industry associations.
Victoria lead the regulatory policy and strategy function in Abbott China and providing Policy Discussion & Communication both within Abbott divisions and with regulatory authorities.
Victoria also contributing and maintaining Abbott’s Industry Association position and lead lobby activities both via China local industry platforms and regional regulatory communities.
Wong Woei Jiuang
Director of Medical Devices Branch, Health Products Regulation Group Health Sciences Authority Singapore
Wong Woei Jiuang is the Director of Medical Devices Branch, Health Products Regulation Group of Health Sciences Authority. The branch is responsible for the pre and post market regulation of medical devices. She currently represents Singapore as a member of the Management Committee of the International Medical Device Regulators Forum (IMDRF) and is also the current Co- Chair of the ASEAN Medical Device Committee. She is a member of the working group that developed the WHO Global Model Regulatory Framework for medical devices.
Previously, Woei Jiuang had worked in several multi-national companies. She was involved in providing regulatory strategies for medical devices in the development stage as well as setting strategic direction for regulatory submissions and ensuring effective implementation in Asia Pacific (South East Asia, China, Japan, Korea, Australia, India) and Middle East.